debest

Duration Estimation for Biomarker Enrichment Studies and Trials

CRAN Package

A general framework using mixture Weibull distributions to accurately predict biomarker-guided trial duration accounting for heterogeneous population. Extensive simulations are performed to evaluate the impact of heterogeneous population and the dynamics of biomarker characteristics and disease on the study duration. Several influential parameters including median survival time, enrollment rate, biomarker prevalence and effect size are identified. Efficiency gains of biomarker-guided trials can be quantitatively compared to the traditional all-comers design. For reference, see Zhang et al. (2024) doi:10.48550/arXiv.2401.00540.

  • Version0.1.0
  • R versionunknown
  • LicenseGPL-2
  • Needs compilation?No
  • Last release01/10/2024

Team


Insights

Last 30 days

Last 365 days

The following line graph shows the downloads per day. You can hover over the graph to see the exact number of downloads per day.

Data provided by CRAN


Binaries


Dependencies

  • Imports2 packages